Do analysts rate BLUW or PLX?

Protalix BioTherapeutics has a consensus price target of $12.00, suggesting a potential upside of 503.02%. Given Protalix BioTherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Protalix BioTherapeutics is more favorable than Blue Water Acquisition Corp. III. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Blue Water Acquisition Corp. III 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Protalix BioTherapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00

Which has higher earnings and valuation, BLUW or PLX?

Protalix BioTherapeutics has higher revenue and earnings than Blue Water Acquisition Corp. III. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Blue Water Acquisition Corp. III N/A N/A N/A N/A N/A Protalix BioTherapeutics $76.38M 2.10 $8.31M $0.18 11.06

Do analysts rate BLUW or JATT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Blue Water Acquisition Corp. III 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 JATT Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation and earnings, BLUW or JATT?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Blue Water Acquisition Corp. III N/A N/A N/A N/A N/A JATT Acquisition N/A N/A $6.85M N/A N/A

Is BLUW or JATT more profitable?

Blue Water Acquisition Corp. III's return on equity of 0.00% beat JATT Acquisition's return on equity. Company Net Margins Return on Equity Return on Assets Blue Water Acquisition Corp. III N/A N/A N/A JATT Acquisition N/A -49.58% 2.84%

Do analysts rate BLUW or IZTC?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Blue Water Acquisition Corp. III 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Invizyne Technologies 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, BLUW or IZTC?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Blue Water Acquisition Corp. III N/A N/A N/A N/A N/A Invizyne Technologies N/A N/A N/A N/A N/A

Is BLUW or IZTC more profitable?

Company Net Margins Return on Equity Return on Assets Blue Water Acquisition Corp. III N/A N/A N/A Invizyne Technologies N/A N/A N/A

Do analysts prefer BLUW or ALVR?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Blue Water Acquisition Corp. III 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 AlloVir 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, BLUW or ALVR?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Blue Water Acquisition Corp. III N/A N/A N/A N/A N/A AlloVir N/A N/A -$190.42M -$20.23 N/A

Is BLUW or ALVR more profitable?

Blue Water Acquisition Corp. III's return on equity of 0.00% beat AlloVir's return on equity. Company Net Margins Return on Equity Return on Assets Blue Water Acquisition Corp. III N/A N/A N/A AlloVir N/A -71.03% -61.27%

Do analysts prefer BLUW or ZIVO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Blue Water Acquisition Corp. III 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ZIVO Bioscience 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, BLUW or ZIVO?

Blue Water Acquisition Corp. III has higher earnings, but lower revenue than ZIVO Bioscience. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Blue Water Acquisition Corp. III N/A N/A N/A N/A N/A ZIVO Bioscience $15.85K 798.97 -$7.78M -$1.71 N/A

Is BLUW or ZIVO more profitable?

Company Net Margins Return on Equity Return on Assets Blue Water Acquisition Corp. III N/A N/A N/A ZIVO Bioscience N/A N/A -2,240.92%

Blue Water Acquisition Corp. III (BLUW) Competitors

$10.32 0.00 (0.00%)

As of 06/5/2026 04:00 PM Eastern

Compare

BLUW vs. PLX, JATT, IZTC, ALVR, and ZIVO

Should you buy Blue Water Acquisition Corp. III stock or one of its competitors? MarketBeat compares Blue Water Acquisition Corp. III with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Blue Water Acquisition Corp. III include Protalix BioTherapeutics (PLX), JATT Acquisition (JATT), Invizyne Technologies (IZTC), AlloVir (ALVR), and ZIVO Bioscience (ZIVO). These companies are all part of the "medical" sector.

How does Blue Water Acquisition Corp. III compare to Protalix BioTherapeutics?

Blue Water Acquisition Corp. III (NASDAQ:BLUW) and Protalix BioTherapeutics (NYSE:PLX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

Protalix BioTherapeutics has higher revenue and earnings than Blue Water Acquisition Corp. III.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Blue Water Acquisition Corp. III	N/A	N/A	N/A	N/A	N/A
Protalix BioTherapeutics	$76.38M	2.10	$8.31M	$0.18	11.06

Protalix BioTherapeutics has a consensus price target of $12.00, suggesting a potential upside of 503.02%. Given Protalix BioTherapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Protalix BioTherapeutics is more favorable than Blue Water Acquisition Corp. III.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Blue Water Acquisition Corp. III	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Protalix BioTherapeutics	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

16.5% of Protalix BioTherapeutics shares are held by institutional investors. 6.5% of Protalix BioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Protalix BioTherapeutics had 1 more articles in the media than Blue Water Acquisition Corp. III. MarketBeat recorded 1 mentions for Protalix BioTherapeutics and 0 mentions for Blue Water Acquisition Corp. III. Blue Water Acquisition Corp. III's average media sentiment score of 0.00 equaled Protalix BioTherapeutics'average media sentiment score.

Company	Overall Sentiment
Blue Water Acquisition Corp. III	Neutral
Protalix BioTherapeutics	Neutral

Blue Water Acquisition Corp. III has a net margin of 0.00% compared to Protalix BioTherapeutics' net margin of -21.03%. Blue Water Acquisition Corp. III's return on equity of 0.00% beat Protalix BioTherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Blue Water Acquisition Corp. III	N/A	N/A	N/A
Protalix BioTherapeutics	-21.03%	-30.89%	-11.74%

Summary

Protalix BioTherapeutics beats Blue Water Acquisition Corp. III on 7 of the 10 factors compared between the two stocks.

How does Blue Water Acquisition Corp. III compare to JATT Acquisition?

Blue Water Acquisition Corp. III (NASDAQ:BLUW) and JATT Acquisition (NYSE:JATT) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, dividends, earnings, valuation, institutional ownership, media sentiment and risk.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Blue Water Acquisition Corp. III	N/A	N/A	N/A	N/A	N/A
JATT Acquisition	N/A	N/A	$6.85M	N/A	N/A

In the previous week, Blue Water Acquisition Corp. III's average media sentiment score of 0.00 equaled JATT Acquisition'saverage media sentiment score.

Company	Overall Sentiment
Blue Water Acquisition Corp. III	Neutral
JATT Acquisition	Neutral

Blue Water Acquisition Corp. III's return on equity of 0.00% beat JATT Acquisition's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Blue Water Acquisition Corp. III	N/A	N/A	N/A
JATT Acquisition	N/A	-49.58%	2.84%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Blue Water Acquisition Corp. III	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
JATT Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

48.0% of JATT Acquisition shares are owned by institutional investors. 20.0% of JATT Acquisition shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

JATT Acquisition beats Blue Water Acquisition Corp. III on 3 of the 5 factors compared between the two stocks.

How does Blue Water Acquisition Corp. III compare to Invizyne Technologies?

Blue Water Acquisition Corp. III (NASDAQ:BLUW) and Invizyne Technologies (NASDAQ:IZTC) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, institutional ownership, earnings, valuation, media sentiment, profitability, analyst recommendations and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Blue Water Acquisition Corp. III	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Invizyne Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

In the previous week, Blue Water Acquisition Corp. III's average media sentiment score of 0.00 equaled Invizyne Technologies'average media sentiment score.

Company	Overall Sentiment
Blue Water Acquisition Corp. III	Neutral
Invizyne Technologies	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Blue Water Acquisition Corp. III	N/A	N/A	N/A
Invizyne Technologies	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Blue Water Acquisition Corp. III	N/A	N/A	N/A	N/A	N/A
Invizyne Technologies	N/A	N/A	N/A	N/A	N/A

Summary

Blue Water Acquisition Corp. III beats Invizyne Technologies on 1 of the 1 factors compared between the two stocks.

How does Blue Water Acquisition Corp. III compare to AlloVir?

Blue Water Acquisition Corp. III (NASDAQ:BLUW) and AlloVir (NASDAQ:ALVR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Blue Water Acquisition Corp. III	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
AlloVir	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

66.1% of AlloVir shares are owned by institutional investors. 32.1% of AlloVir shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Blue Water Acquisition Corp. III's average media sentiment score of 0.00 equaled AlloVir'saverage media sentiment score.

Company	Overall Sentiment
Blue Water Acquisition Corp. III	Neutral
AlloVir	Neutral

Blue Water Acquisition Corp. III's return on equity of 0.00% beat AlloVir's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Blue Water Acquisition Corp. III	N/A	N/A	N/A
AlloVir	N/A	-71.03%	-61.27%

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Blue Water Acquisition Corp. III	N/A	N/A	N/A	N/A	N/A
AlloVir	N/A	N/A	-$190.42M	-$20.23	N/A

Summary

Blue Water Acquisition Corp. III beats AlloVir on 3 of the 5 factors compared between the two stocks.

How does Blue Water Acquisition Corp. III compare to ZIVO Bioscience?

Blue Water Acquisition Corp. III (NASDAQ:BLUW) and ZIVO Bioscience (NASDAQ:ZIVO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, dividends, valuation, profitability, risk, earnings, institutional ownership and media sentiment.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Blue Water Acquisition Corp. III	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ZIVO Bioscience	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

12.8% of ZIVO Bioscience shares are owned by institutional investors. 48.9% of ZIVO Bioscience shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, ZIVO Bioscience had 1 more articles in the media than Blue Water Acquisition Corp. III. MarketBeat recorded 1 mentions for ZIVO Bioscience and 0 mentions for Blue Water Acquisition Corp. III. Blue Water Acquisition Corp. III's average media sentiment score of 0.00 equaled ZIVO Bioscience'saverage media sentiment score.

Company	Overall Sentiment
Blue Water Acquisition Corp. III	Neutral
ZIVO Bioscience	Neutral

Company	Net Margins	Return on Equity	Return on Assets
Blue Water Acquisition Corp. III	N/A	N/A	N/A
ZIVO Bioscience	N/A	N/A	-2,240.92%

Blue Water Acquisition Corp. III has higher earnings, but lower revenue than ZIVO Bioscience.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Blue Water Acquisition Corp. III	N/A	N/A	N/A	N/A	N/A
ZIVO Bioscience	$15.85K	798.97	-$7.78M	-$1.71	N/A

Summary

ZIVO Bioscience beats Blue Water Acquisition Corp. III on 4 of the 6 factors compared between the two stocks.

Get Blue Water Acquisition Corp. III News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLUW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BLUW vs. The Competition

Export

Metric	Blue Water Acquisition Corp. III	Biological Products, Except Diagnostic Industry	Medical Sector	NASDAQ Exchange
Market Cap	$290.20M	$349.49M	$6.68B	$11.99B
Dividend Yield	N/A	N/A	2.67%	5.55%
P/E Ratio	N/A	N/A	24.01	23.62
Price / Sales	N/A	143.64	519.33	112.45
Price / Cash	N/A	22.44	42.23	54.60
Price / Book	N/A	4.72	9.73	6.35
Net Income	N/A	-$141.03M	$3.57B	$337.59M
7 Day Performance	0.49%	-5.75%	-1.26%	-2.51%
1 Month Performance	0.58%	-5.49%	0.82%	-0.69%
1 Year Performance	7.17%	54.81%	24.09%	25.37%

Blue Water Acquisition Corp. III Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BLUW Blue Water Acquisition Corp. III	N/A	$10.32 flat	N/A	+7.2%	$290.20M	N/A	N/A	2	High Trading Volume
PLX Protalix BioTherapeutics	2.5579 of 5 stars	$2.11 +0.5%	$12.00 +468.7%	+30.9%	$170.01M	$76.38M	N/A	200
JATT JATT Acquisition	N/A	$10.51 +0.9%	N/A	+778.4%	$81.28M	N/A	N/A	3
IZTC Invizyne Technologies	N/A	$9.85 +1.3%	N/A	-30.7%	$61.55M	N/A	N/A	29	Gap Up
ALVR AlloVir	N/A	$5.27 +1.7%	N/A	+50.8%	$49.48M	N/A	N/A	110	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BLUW) was last updated on 6/6/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blue Water Acquisition Corp. III (BLUW) Competitors

BLUW vs. PLX, JATT, IZTC, ALVR, and ZIVO

How does Blue Water Acquisition Corp. III compare to Protalix BioTherapeutics?

Summary

How does Blue Water Acquisition Corp. III compare to JATT Acquisition?

Summary

How does Blue Water Acquisition Corp. III compare to Invizyne Technologies?

Summary

How does Blue Water Acquisition Corp. III compare to AlloVir?

Summary

How does Blue Water Acquisition Corp. III compare to ZIVO Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLUW vs. The Competition

Blue Water Acquisition Corp. III Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Blue Water Acquisition Corp. III (BLUW) Competitors

BLUW vs. PLX, JATT, IZTC, ALVR, and ZIVO

How does Blue Water Acquisition Corp. III compare to Protalix BioTherapeutics?

Which has higher earnings and valuation, BLUW or PLX?

Do analysts rate BLUW or PLX?

Do institutionals and insiders believe in BLUW or PLX?

Does the media refer more to BLUW or PLX?

Is BLUW or PLX more profitable?

Summary

How does Blue Water Acquisition Corp. III compare to JATT Acquisition?

Which has better valuation and earnings, BLUW or JATT?

Does the media prefer BLUW or JATT?

Is BLUW or JATT more profitable?

Do analysts rate BLUW or JATT?

Do institutionals and insiders have more ownership in BLUW or JATT?

Summary

How does Blue Water Acquisition Corp. III compare to Invizyne Technologies?

Do analysts rate BLUW or IZTC?

Does the media favor BLUW or IZTC?

Is BLUW or IZTC more profitable?

Which has higher valuation & earnings, BLUW or IZTC?

Summary

How does Blue Water Acquisition Corp. III compare to AlloVir?

Do analysts prefer BLUW or ALVR?

Do institutionals & insiders have more ownership in BLUW or ALVR?

Does the media refer more to BLUW or ALVR?

Is BLUW or ALVR more profitable?

Which has higher earnings and valuation, BLUW or ALVR?

Summary

How does Blue Water Acquisition Corp. III compare to ZIVO Bioscience?

Do analysts prefer BLUW or ZIVO?

Do institutionals & insiders have more ownership in BLUW or ZIVO?

Does the media refer more to BLUW or ZIVO?

Is BLUW or ZIVO more profitable?

Which has higher earnings and valuation, BLUW or ZIVO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BLUW vs. The Competition

Blue Water Acquisition Corp. III Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools